Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15+
SponsorCentral South University

About this trial

Autoimmune encephalitis (AE) is a potentially life-threatening inflammation of the central nervous system (CNS) and constitutes 20%-30% of encephalitis cases in adults AE often leads to subacute, severe, and debilitating encephalitis necessitating long-term management in a neurologic intensive care unit (ICU). This study aims to explore the predictive factors for poor clinical outcomes by analyzing the clinical characteristics and prognosis of adult patients with critical AE requiring ICU admission. Prospective observational single center study in neurologic ICU, the second Xiangya hospital, Central South University. All patients admitted to the ICU for probable or confirmed AE (2022 Chinese guidelines for diagnosis and treatment of AE) will be included. Factors associated with a poor prognosis will be identified by multivariate analysis using a logistic regression.

Eligibility criteria

Qualifiers

Diagnosed as either ''definite'' or ''probable'' AE based on Chinese guidelines for diagnosis and treatment of AE (version 2022)

Age ≥ 15 years

Admission to an adult ICU during the course of the disease

Disqualifiers

Missing data on primary outcome

ICU length of stay of 24 hours or less.

Trial design

Treatments tested in this trial

  • None, non-interventional study

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators